^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Dupert (fulzerasib) (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
Excerpt:
...- Pathologically diagnosed, previously treated, advanced tumor with KRAS p.G12C mutation...
Trial ID:
Source:
Title:
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
Excerpt:
...have documentation of KRAS G12C mutation 3....
Trial ID:
Less C2 evidence
Source:
Title:
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Published date:
11/27/2023
Excerpt:
The updated results of IBI351 (GFH925) monotherapy showed promising durable efficacy and manageable safety in metastatic CRC harboring KRASG12C mutation.
Trial ID:
Source:
Title:
Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Preliminary results from a pooled analysis of two phase I studies.
Published date:
05/25/2023
Excerpt:
IBI351 (GFH925) monotherapy demonstrated promising anti-tumor activity with manageable safety profile in metastatic CRC patients harboring KRAS G12C mutation.
DOI:
10.1200/JCO.2023.41.16_suppl.3586
Trial ID:
Title:
Innovent Presents Clinical Data of Phase Ia Study for IBI351 (KRASG12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting
Published date:
11/15/2022
Excerpt:
Favorable safety and tolerability and promising antitumor activity of IBI351 monotherapy were observed in previously-treated advanced NSCLC, CRC and pancreatic cancer harboring KRASG12C mutation.
Trial ID:
